[ source from：The pharma letter ] Metabolic and digestive disease specialist HighTide Therapeutics has raised S107 million in aseries C financing led by China's TCM Healthcare Fund, with money also from Yuexiu Fundand Yuthai Fund.

[ 文章来源：中国证券报 ] 元旦刚过，创新药赛道传来“开门红”消息，近日，君圣泰医药宣布完成1.07亿美元C/C+轮融资。该轮融资由国开金融及广东国资委管理的广东中医药大健康基金领投，越秀产业基金、昱烽晟泰旗下基金百亿资本及相关企业参与投资。君圣泰创始人、首席执行官刘利平表示，本轮募集资金将用于推进君圣泰在研管线产品的多项临床中后期全球开发、商业化和商务拓展，团队将继续努力，以期早日把安全、有效的原创新药带给全球患者。 广东中医药大健康基金董事长刘江波认为，

[ source from：Endpoints News ] HighTide Therapeutics has raised a $107 million Series C round to fund mid-stage studies in metabolic and digestive diseases, with the goal of filing for approval in China within two to three years.